RITE ZONE CHEMCON INDIA LIMITED

Our Company was originally incorporated as "Rite Zone Chemicals India Private Limited'' on March 10, 2015, as a private limited company under the provisions of the Companies Act, 2013 pursuant to Certificate of Incorporation issued by Registrar of Companies, Maharashtra, Mumbai. Subsequently, our Company pursuant to shareholder's resolution passed at the Extra-Ordinary General Meeting held on 7th April, 2022 changed the name of the Company from "Rite Zone Chemicals India Private Limited'' to "Rite Zone Chemcon India Private Limited". Our Company was converted into a Public Limited Company pursuant to special resolution passed by our shareholders at the Extra-Ordinary General Meeting of our Company held on May 18, 2022 and the name of our Company was changed to "Rite Zone Chemcon India Limited". A Fresh Certificate of Incorporation consequent upon conversion to public limited company was issued by the Registrar of Companies, Mumbai, Maharashtra on June 2, 2022. The Corporate Identification Number of our Company is U24100MH2015PLC262574. For details of incorporation, change of name and registered office of our Company, please refer to chapter titled ‘General Information' and "History and Certain Corporate Matters" beginning on page 49 and 111 respectively of the Prospectus.

Our Company has filed the Prospectus dated October 21, 2022 with the RoC, and the Equity Shares are proposed to be listed on National Stock Exchange of India Limited ("NSE") and trading will commence on November 11, 2022*.

THIS ISSUE IS BEING MADE IN TERMS OF CHAPTER IX OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018 (THE "SEBI (ICDR) REGULATIONS"), AS AMENDED. IN TERMS OF RULE 19(2)(B)(I) OF THE SECURITIES CONTRACTS (REGULATION) RULES, 1957, AS AMENDED, THIS IS AN ISSUE FOR AT LEAST 25% OF THE POST-ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY. THIS ISSUE IS A FIXED PRICE ISSUE AND ALLOCATION IN THE NET ISSUE TO THE PUBLIC WILL BE MADE TERMS OF REGULATION 253 OF THE SEBI (ICDR) REGULATIONS, 2018 AS AMENDED.

As per Regulation 253(2) of the SEBI (ICDR) Regulations, as amended, as present issue is a fixed price offer the allocation in the net offer to the public category shall be made as follows:

a) Minimum fifty percent to retail individual investors; and

b) Remaining to other investors including corporate bodies or institutions, irrespective of the number of specified securities applied for;

Provided that the unsubscribed portion in either of the categories specified in (a) or (b) above may be allocated to the applicants in the other category.

If the retail individual investor category is entitled to more than fifty per cent on proportionate basis, accordingly the retail individual investors shall be allocated that higher percentage.

*Subject to the receipt of listing and trading approval from NSE Emerge.

The Equity Shares offered through the Prospectus are proposed to be listed on the EMERGE Platform of National Stock Exchange of India Limited ("NSE") in terms of the Chapter IX of the SEBI (ICDR) Regulations, as amended from time to time. Our Company has received an approval letter dated October 18, 2022 from National Stock Exchange of India Limited ("NSE") for using its name in the Offer Document for listing of our shares on the Emerge Platform of NSE. For the purpose of this Issue, NSE is the Designated Stock Exchange. The trading is proposed to be commenced on or about Friday, November 11, 2022*.

*Subject to the receipt of listing and trading approval from the NSE EMERGE Platform.

All Applicants were allowed to participate in the Issue through APPLICATIONS SUPPORTED BY BLOCKED AMOUNT ("ASBA") process by providing the details of their respective bank accounts in which the corresponding application amounts were blocked by Self Certified Syndicate Banks (the "SCSBs"). Further, for UPI Applicants (Investors biding for amount upto Rs. 5 Lacs) use of UPI Id in Application Form was allowed while applying for equity IPOs through Designated Intermediaries (Syndicate members, Registered Stock Brokers, Registrar and Transfer agent and Depository Participants). All Other Category of Investors shall mandatorily use only Application Supported by Blocked Amount (ASBA) facility for making payments. Subsequently, pursuant to SEBI circular no SEBI/HO/CFD/DIL2/P/CIR/2022/75 dated May 30, 2022, applications made using the ASBA facility in initial public offerings (opening on or after September 1, 2022) shall be processed only after application monies are blocked in the bank accounts of investors (all categories).

The Issue has received 3,702 applications for 71,58,400 Equity Shares resulting in 5.99 times subscription before technical rejections and bids not banked (including reserved portion of Market Maker). The Issue has received 2,587 applications for 52,12,800 Equity Shares resulting in 4.36 times subscription after technical rejections and bids not banked (including reserved portion of Market Maker).

Detail of Applications Received (Before Technical Rejection and bids not banked):

Details of Applications rejected by the Registrar on technical grounds and bids not banked:

After eliminating technically rejected applications and bids not banked, the following table gives the details of Category wise net valid applications:

Allocation: The Basis of Allotment was finalized in consultation with the Designated Stock Exchange - NSE on November 7, 2022.

The Board of Directors of the Company at its meeting held on November 7, 2022 has taken on record the Basis of Allocation of Equity Shares approved by the Designated Stock Exchange viz. NSE and has authorized the corporate action for the transfer of the Equity Shares to various successful applicants.

The Refund/allotment intimation will be dispatched to the address of the Applicants as registered with the depositories on or about November 9, 2022. Further, the instructions to Self Certified Syndicate Banks for unblocking the amount have been processed on or prior to November 7, 2022. In case the same is not received within ten days, investors may contact Registrar at the address given below.

The Equity Shares allocated to successful applicants are being credited to their beneficiary accounts subject to validation of the account details with the depositories concerned. The Company is taking steps to get the Equity Shares admitted for trading on Emerge Platform of NSE within six working days from the date of the closure of the Issue.

Note: All capitalized terms used and not defined herein shall have the respective meaning assigned to them in the Prospectus dated October 21, 2022 ("Prospectus").

INVESTORS, PLEASE NOTE

The details of the allotment made would also be hosted on the website of the Registrar to the Issue Skyline Financial Services Private Limited at www.skylinerta.com. All future correspondence in this regard may kindly be addressed to the Registrar to the Issue quoting full name of the First/ Sole Applicant, Serial number of the Application Form, number of Equity Shares applied for, Applicant DP ID, Client ID, PAN, date of submission of the Application Form, address of the Applicant, the name and address of the Designated Intermediary where the Application Form was submitted by the Applicant and copy of the Acknowledgment Slip received from the Designated Intermediary and payment details at the address given below:

	SKYLINE FINANCIAL SERVICES PRIVATE LIMITED
	D-153A, 1st Floor, Okhla Industrial Area, Phase-I, New Delhi -110020, India;
	Telephone: 011-40450193-197; Facsimile: 011-26812683; Email: ipo@skylinerta.com;
	Investor Grievance Email: grievances@skylinerta.com; Contact Person: Ms. Rati Gupta Website: www.skylinerta.com SEBI Registration Number: INR000003241 CIN: U74899DL1995PTC071324

THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARE ON LISTING OR THE BUSINESS PROSPECTS OF RITE ZONE CHEMCON INDIA LIMITED.

Disclaimer: Rite Zone Chemcon India Limited has filed the Prospectus dated October 21, 2022 with the Registrar of Companies, Maharashtra and thereafter with SEBI and the Stock Exchange. The Prospectus is available on the website of NSE EMERGE i.e. www1.nseindia.com/emerge/  and is available on the website of the BRIM at www.expertglobal.in. Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, please refer to the Prospectus including the section titled "Risk Factors " beginning on page 25 of the Prospectus.

The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or any state securities laws in the United States, and unless so registered, and may not be issued or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with any applicable U.S. state securities laws. The Equity Shares are being issued and sold outside the United States in ‘offshore transactions' in reliance on Regulation "S" under the Securities Act and the applicable laws of each jurisdiction where such issues and sales are made. There will be no public offering in the United States